ABSTRACT
This chapter is inspired by US Patent Application 20020168424, Nitric Oxide (NO) Donor + cGMP-PDE5 Inhibitor as a Topical Drug for Glaucoma. It is also inspired by 20020168424 (https://www.pat2pdf.org" xmlns:xlink="https://www.w3.org/1999/xlink">pat2pdf.org).
A new topical drug (ointment or eye drop) for treating glaucoma or ocular hypertension in patients comprises a mixture of a nitric oxide (NO) donor—such as nitrovasodilators like minoxidil, nitroglycerin, L-arginine, isosorbide dinitrate, or nitroprusside—and a cyclic guanosine 3’,5’-monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) inhibitor—such as sildenafil citrate (Viagra.sup. RTM)—in an ophthalmologically acceptable solution mix. In this manner, there will be increased blood circulation to the optic nerve and the ocular hypotensive effect of the combined compounds is enhanced synergistically.
